Physician profile
Reena Thomas
NPI 1871936534
$1,397.44
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $61.90 · 2021: $232 · 2022: $875.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $470.29 | 2019-2022 | |
| Glaxosmithkline, LLC. | $334.66 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $277.70 | 2022 | |
| Global Blood Therapeutics, INC. | $229.22 | 2021-2022 | |
| Dynavax Technologies Corporation | $26.45 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $21.35 | 2022 | |
| Mannkind Corporation | $19.09 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.68 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.